logo-loader
viewScancell Holdings PLC

Scancell to receive patent protection for key cancer platform

Once formally granted, the patent will provide protection for Scancell’s pipeline of Moditope vaccines

patents
This is a key case for the company as we progress development of our Moditope platform - said chief executive Cliff Holloway

Scancell Holdings Plc (LON:SCLP) said the European Patent Office intends to grant the company’s patent application for the Moditope immunotherapy platform.

Once formally granted the patent will provide protection for Scancell’s pipeline of Moditope vaccines that could help revolutionise the way cancer is treated.

READ: Scancell-led team short-listed for award

The patent will cover all major areas in Europe, while similar filings have been made in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

"By confirming its intention to grant this patent application, the European Patent Office has continued to uphold the validity of Scancell's expanding patent estate,” said chief executive Cliff Holloway. 

“This is a key case for the company as we progress development of our Moditope platform and provides further protection for Scancell's innovative cancer vaccine technologies."

Quick facts: Scancell Holdings PLC

Price: 5.05 GBX

LSE:SCLP
Market: LSE
Market Cap: £23.5 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibody collaboration deal for Scancell

Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly. CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing...

on 5/9/19

2 min read